Clindamycin
Clindamycin hydrochloride / Clindamycin phosphate
Brand names:Cleocin, Cleocin T, Clinda-Derm
A lincosamide antibiotic with strong gram-positive and anaerobic coverage, used in tactical medicine for skin and soft tissue infections in penicillin-allergic casualties and for community-acquired MRSA coverage in austere environments. Clindamycin's broad anaerobic spectrum makes it useful in dental, head/neck, and complicated soft tissue infections.
Pharmacology and Actions
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation. The drug is generally bacteriostatic but can be bactericidal at higher concentrations or against highly susceptible organisms. Spectrum includes Staphylococcus aureus (including many community-acquired MRSA strains), Streptococcus species, anaerobes including Bacteroides, Clostridium perfringens, and Peptostreptococcus. Notable lack of activity against most gram-negative organisms.
Indications
- Skin and soft tissue infection in penicillin-allergic casualties
- Community-acquired MRSA skin and soft tissue infections
- Severe Group A Streptococcus infections (toxin suppression in necrotizing fasciitis)
- Dental infections and odontogenic facial space infections
- Anaerobic coverage in penicillin-allergic patients with intra-abdominal or pelvic infection
- Aspiration pneumonia in patients allergic to first-line agents
- Toxic shock syndrome (adjunct for toxin suppression)
Absolute Contraindications
- Known clindamycin or lincosamide allergy
- History of severe antibiotic-associated colitis with prior clindamycin use
- Concurrent severe Clostridioides difficile infection (relative)
Precautions and Side Effects
Clindamycin is associated with one of the highest rates of Clostridioides difficile colitis of any antibiotic. Diarrhea during or after treatment should prompt evaluation for C. difficile. Other common adverse effects include nausea, vomiting, rash, and esophageal irritation with oral preparations (take with full glass of water and remain upright). Neuromuscular blockade can occur with high doses or in combination with other neuromuscular blockers. Hepatic dose adjustment may be required.
Adult Dosing
Pediatric Dosing
Pediatric dosing: 25 to 40 mg/kg/day PO divided every 6 to 8 hours for serious infections. IV: 20 to 40 mg/kg/day divided every 6 to 8 hours. Maximum daily dose 4.8 grams. Pediatric tactical use is uncommon.
Pharmacokinetics
Peak Effect: PO: 45 to 60 minutes. IV: end of infusion.
Duration: 6 to 8 hours per dose
Storage and Handling
Store capsules at controlled room temperature (15 to 30 degrees Celsius). Protect from moisture. Oral solution and IV preparation have specific storage requirements per manufacturer.
Reconstitution:
Capsules require no reconstitution. IV preparation is supplied as a ready-to-dilute solution; further dilution in 50 to 100 mL NSS or D5W is required before infusion. Do not administer undiluted IV bolus.
TCCC and TECC Role
Clindamycin is positioned in TCCC and tactical medicine as the alternative oral antibiotic for skin and soft tissue infections in casualties with documented penicillin and cephalosporin allergy, and as community-acquired MRSA coverage when methicillin-resistant Staphylococcus is suspected. The drug's anaerobic coverage extends its utility to dental infections, head/neck space infections, and as the second drug for anaerobic coverage in beta-lactam allergic casualties with intra-abdominal injuries.
Clindamycin is the drug for the casualty who cannot take a cephalosporin and has a wound that is likely MRSA or has significant anaerobic contamination. The trade-off is the C. difficile risk, which is real and not theoretical. Use clindamycin when indicated, but consider that any antibiotic stewardship in the field setting reduces collateral damage. The drug is excellent for dental abscesses, which can be a real operational problem in deployment settings.
Using clindamycin as a default broad-spectrum antibiotic without considering the C. difficile risk and the lack of gram-negative coverage. Clindamycin should not be used as a substitute for cephalosporins in casualties without true beta-lactam allergy. For gram-negative coverage or comprehensive wound prophylaxis, clindamycin must be paired with a fluoroquinolone or other agent.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Clindamycin
| IV/IO | Severe infection: 600 to 900 mg IV every 8 hours. Infuse over 30 to 60 minutes. Maximum 4.8 grams/day. (Immediate after infusion) |
| IM | 300 to 600 mg IM every 8 to 12 hours for moderate infections when IV not available. (30 to 60 minutes) |
| PO | Adult standard dosing: 300 to 450 mg PO every 6 to 8 hours. TCCC alternative for skin and soft tissue infection in penicillin-allergic casualty: 450 mg PO every 6 hours. (30 minutes to 1 hour (90 percent bioavailability)) |